Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes Export

@article{citeulike:1005550, abstract = {Paclitaxel (Taxol) is a diterpenoid isolated from Taxus brevifolia, approved by the FDA for the treatment of ovarian and breast cancers. Due to its low solubility in water, it is clinically administered dissolved in Cremophor EL, (polyethoxylated castor oil) and ethanol, which cause serious side effects. Inclusion of paclitaxel in liposomal formulations has proved to be a good approach to eliminating this vehicle and improving the drug's antitumor efficacy. We prepared different conventional and PEGylated liposomes containing paclitaxel and determined encapsulation efficiency, physical stability and drug leakage in human plasma. The best conventional liposome formulation was composed of ePC/PG 9:1, while for PEGylated liposomes the best composition was ePC/PG/CHOL/PEG5000-DPPE 9:1:2:0.7. PEGylated liposomes were found to be less stable during storage than the corresponding conventional liposomes and to have lower drug release in human plasma at 37[deg]C. In vitro cytotoxic activities were evaluated on HT-29 human colon adenocarcinoma and MeWo melanoma cell lines. After 2 and 48 h, conventional liposomes had the same cytotoxicity as free paclitaxel, while PEGylated liposomes were as active as free drug, only after 48 h. Pharmacokinetics and biodistribution were evaluated in Balb/c mice after i.v. injection of paclitaxel, formulated in Cremophor EL or in conventional or in PEGylated liposomes. Encapsulation of paclitaxel in conventional liposomes produced marked differences over the free drug pharmacokinetics. PEGylated liposomes were long-circulating liposomes, with an increased t1/2 [beta] 48.6 h, against t1/2 [beta] 9.27 h of conventional liposomes. Biodistribution studies showed a considerable decrease in drug uptake in MPS-containing organs (liver and spleen) at 0.5 and 3 h after injection with PEGylated compared to conventional liposomes.}, author = {Crosasso, Paola and Ceruti, Maurizio and Brusa, Paola and Arpicco, Silvia and Dosio, Franco and Cattel, Luigi}, citeulike-article-id = {1005550}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/S0168-3659(99)00166-2}, citeulike-linkout-1 = {http://www.sciencedirect.com/science/article/B6T3D-3YB4CNV-3/2/9f44977bd9d3c5f27443cef2ed62a8e3}, comment = {Hplc, stability (look)}, day = {3}, doi = {10.1016/S0168-3659(99)00166-2}, journal = {Journal of Controlled Release}, keywords = {drug, insol, methods}, month = {January}, number = {1-2}, pages = {19--30}, posted-at = {2006-12-21 07:46:16}, priority = {0}, title = {Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes}, url = {http://dx.doi.org/10.1016/S0168-3659(99)00166-2}, volume = {63}, year = {2000} }

TY - JOUR ID - citeulike:1005550 L3 - citeulike-article-id:1005550 N2 - Paclitaxel (Taxol) is a diterpenoid isolated from Taxus brevifolia, approved by the FDA for the treatment of ovarian and breast cancers. Due to its low solubility in water, it is clinically administered dissolved in Cremophor EL, (polyethoxylated castor oil) and ethanol, which cause serious side effects. Inclusion of paclitaxel in liposomal formulations has proved to be a good approach to eliminating this vehicle and improving the drug's antitumor efficacy. We prepared different conventional and PEGylated liposomes containing paclitaxel and determined encapsulation efficiency, physical stability and drug leakage in human plasma. The best conventional liposome formulation was composed of ePC/PG 9:1, while for PEGylated liposomes the best composition was ePC/PG/CHOL/PEG5000-DPPE 9:1:2:0.7. PEGylated liposomes were found to be less stable during storage than the corresponding conventional liposomes and to have lower drug release in human plasma at 37[deg]C. In vitro cytotoxic activities were evaluated on HT-29 human colon adenocarcinoma and MeWo melanoma cell lines. After 2 and 48 h, conventional liposomes had the same cytotoxicity as free paclitaxel, while PEGylated liposomes were as active as free drug, only after 48 h. Pharmacokinetics and biodistribution were evaluated in Balb/c mice after i.v. injection of paclitaxel, formulated in Cremophor EL or in conventional or in PEGylated liposomes. Encapsulation of paclitaxel in conventional liposomes produced marked differences over the free drug pharmacokinetics. PEGylated liposomes were long-circulating liposomes, with an increased t1/2 [beta] 48.6 h, against t1/2 [beta] 9.27 h of conventional liposomes. Biodistribution studies showed a considerable decrease in drug uptake in MPS-containing organs (liver and spleen) at 0.5 and 3 h after injection with PEGylated compared to conventional liposomes. IS - 1-2 JF - Journal of Controlled Release EP - 30 TI - Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes VL - 63 SP - 19 KW - drug KW - insol KW - methods N1 - Hplc, stability (look) AU - Crosasso, Paola AU - Ceruti, Maurizio AU - Brusa, Paola AU - Arpicco, Silvia AU - Dosio, Franco AU - Cattel, Luigi PY - 2000/01/03/ UR - http://dx.doi.org/10.1016/S0168-3659(99)00166-2 ER -